Search
Researchers from Memorial Sloan Kettering Cancer Center (MSK) shared new data from a survey of members of the Society of Gynecologic Oncology (SGO) showing that sexual harassment and observed gender discrimination continue to be significant issues in the medical community. The results of the study found that more than 60 percent of gynecologic oncologists had experienced sexual harassment, while only 10 percent of survey respondents reported the incident. The findings were presented as part of the press program for this year’s annual meeting of the American Society of Clinical Oncology (ASCO).
The Lisa and Scott Stuart Center for Adolescent and Young Adult Cancers will revolutionize cancer treatment for people ages 15 to 39.
An effective treatment may have emerged for some people with uveal melanoma, a rare cancer that forms in the eye.
Physician-in-Chief Lisa M. DeAngelis joins healthcare experts during the AACR Virtual Meeting: COVID-19 and Cancer to discuss how to safely bring patients to the clinic so they can receive vital cancer screenings and care.
Scientists came to give talks and celebrate the achievements that the program has made under the leadership of Kathryn Anderson.
New data from researchers at Memorial Sloan Kettering Cancer Center (MSK) featured in the 2021 ASCO Annual Meeting press program highlights a promising new treatment option for individuals previously treated for metastatic castration-resistant prostate cancer (mCRPC).
Learn about the breast cancer type called ductal carcinoma in situ (DCIS) and how doctors decide on the best treatment for each person.
While there has been remarkable progress in the number of people surviving with stage 4 cancer, MSK remains dedicated to research that will spur much needed advances.
Using stem cells, scientists can create batches of cortical neurons to study schizophrenia and autism.
A team of Memorial Sloan Kettering researchers reports that prostate cancer often takes an aggressive course in patients who have inherited mutations in the genes BRCA1 or BRCA2.